CDK4 and interstitial lung disease: Moreover, the potential relationship between physiochemical/pharmacokinetic features (e.g., lung distribution) and ILD occurrence should be explored; of note, abemaciclib possesses higher lipophilicity vs other CDK4/6 inhibitors.